RxDoctor Payments Data

Jane Mossberg, MD

Internal Medicine · Eugene, ORNPI 1568573053

Payments from drug & device makers

$2,087in general payments, 2019–2025

Across 148 payments — averaging $14.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$509
  • Novo Nordisk$421
  • AbbVie$327
  • AstraZeneca$326
  • Pfizer$269
  • Exact Sciences$58
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$2,05198%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,087 in reported general payments places this provider in the 90th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$46,647
Medicare patients
138
Services billed
643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$80,654
XareltoRivaroxaban26$30,761
Repatha SureclickEvolocumab37$28,576
MounjaroTirzepatide22$28,202
VraylarCariprazine Hcl16$24,281
JanuviaSitagliptin Phosphate22$22,107
Repatha SyringeEvolocumab26$21,638
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,142
Liothyronine Sodium100$6,549
Desvenlafaxine Succinate ErDesvenlafaxine Succinate64$6,433
Levothyroxine Sodium437$5,310
Colestipol Hcl21$5,303
Nebivolol Hcl69$4,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,385
Gabapentin175$3,892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$269$82,08291 claims
Johnson & JohnsonXarelto$13$30,76126 claims
AbbVieVraylar, Synthroid$327$25,63640 claims
AstraZenecaBreztri Aerosphere$326$8,14211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →